Question follow-through · 106401
Liver Diseases: Medical Treatments
To ask the Secretary of State for Health and Social Care, when he expects treatments for fatty liver disease to be approved for use on the NHS; what assessment he has made of the readiness of the NHS to make such treatments available; and what steps he is
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 16 Jan 2026
- Target answer date
- 20 Jan 2026
- Answer
- 6 Feb 2026 · 21 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
More questions by this MP on Health and care
- Chronic Obstructive Pulmonary Disease: Community Health Services · 24 Feb 2026
- Liver Diseases: Health Services · 24 Apr 2026
- Metabolic Dysfunction-associated Steatohepatitis · 13 May 2026
- Cancer: Children and Young People · 8 Jul 2026
- Health Services: Privacy · 28 Aug 2026
Shared topic keywords suggest a connection; they do not establish a follow-up.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
16 Jan 2026
Question tabled
To ask the Secretary of State for Health and Social Care, when he expects treatments for fatty liver disease to be approved for use on the NHS; what assessment he has made of the readiness of the NHS to make such treatments available; and what steps he is
20 Jan 2026
Target answer date
Date supplied by the official written-questions record.
6 Feb 2026
Answer published
Newly licensed medicines are appraised by the National Institute for Health and Care Excellence (NICE), which is the independent body responsible for developing evidence-based guidance for the National Health Service on whether new medicines represent a c...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
Chronic Obstructive Pulmonary Disease: Community Health Services
24 Feb 2026 · To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that patients with chronic obstructive pulmonary disease receive community-based care with specialist input; and what assessment he has made of the effectiveness o
Liver Diseases: Health Services
24 Apr 2026 · To ask the Secretary of State for Health and Social Care, whether the liver transformation programme led by the Hepatobiliary and Pancreas Clinical Reference Group will include a specific work stream to help address the unmet clinical need in metabolic dy
Metabolic Dysfunction-associated Steatohepatitis
13 May 2026 · To ask the Secretary of State for Health and Social Care, whether the transformation of liver services programme led by the NHS England Hepatobiliary and Pancreas Clinical Reference Group will include a specific workstream to help address the unmet clinic
Cancer: Children and Young People
8 Jul 2026 · To ask the Secretary of State for Health and Social Care, what steps he is taking to increase the detection and diagnosis of cancer in children and young people.
Health Services: Privacy
28 Aug 2026 · To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure NHS England's guidance on single-sex accommodation, wards and intimate care is brought into line with the Supreme Court judgment and the updated EHRC Code.